2-chloro-5-methyl-3-(trifluoromethyl)pyridine | 79424-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-5-methyl-3-(trifluoromethyl)pyridine
• 英文别名: 2-chloro-3-trifluoromethyl-5-methylpyridine
• CAS: 79424-50-3
• 化学式: C₇H₅ClF₃N
• 分子量: 195.572
• InChiKey: SKJFIDMGDCLLJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-5-methyl-3-(trifluoromethyl)pyridine 、 5-[(1R)-6-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazolidine-2,4-dione 在 caesium carbonate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 0.5h， 生成 5-[(1R)-6-[5-methyl-3-(trifluoromethyl)pyridin-2-yl]oxy-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazolidine-2,4-dione
  参考文献：
  名称：

  WO2006/83781

  摘要：

  公开号：

文献信息

• [EN] IMIDAZOPYRIDINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA4BÊTA7
  申请人：GILEAD SCIENCES INC

  公开号：WO2020092394A1

  公开（公告）日：2020-05-07

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供一种如下式（I）的化合物或其药用可接受盐。本公开还提供包含如下式（I）化合物的药物组合物，制备如下式（I）化合物的方法，以及治疗炎症性疾病的治疗方法。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20170267660A1

  公开（公告）日：2017-09-21

  Disclosed are compounds of Formula I(b): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R 3 , R 4 , R 5 , each R 7 , and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

  公开了Formula I(b)的化合物：或其药用可接受的盐、溶剂化合物、互变异构体、异构体或氘代谱，其中环A、环HD、J、每个T、R3、R4、R5、每个R7和m如本公开中所述的任何实施方式中所描述；其组合物；以及其用途。
• SYNTHESIS OF THIOHYDANTOINS
  申请人：Ouerfelli Ouathek

  公开号：US20100190991A1

  公开（公告）日：2010-07-29

  A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.

  提供了一种新颖的抗雄激素A52的合成方法，该药物已被发现在前列腺癌治疗中有用。通过这种创新的方法，可以制备A52及其结构相关的类似物。这种新的合成方案可以用于制备千克级纯A52。
• ANDROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Aragon Pharmaceuticals, Inc.

  公开号：EP3124481A1

  公开（公告）日：2017-02-01

  Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.

  本文描述的化合物是雄激素受体调节剂。还描述了包括本文所述化合物的药物组合物和药物，以及使用此类雄激素受体调节剂（单独使用或与其他化合物结合使用）治疗介导或依赖于雄激素受体的疾病或病症的方法。
• DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3666772A1

  公开（公告）日：2020-06-17

  The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

  本申请属于医药领域。具体而言，本申请涉及一种作为雄激素受体拮抗剂的二芳基硫代海因化合物或其药学上可接受的盐、其制备方法、包含该化合物的药物组合物以及其在治疗由雄激素介导的细胞增殖性疾病中的用途。本申请的化合物对雄激素受体具有良好的拮抗作用，并表现出优异的抗肿瘤效果。